直 Japanese PDF Font
  • 我们的专业人员
  • 服务
  • 我们的见解
  • 办公室
  • 事务所
  • 人才招聘
Finnegan
  • 新闻
  • 飞翰事实
  • History
    • Finnegan VISION
    • Finnegan FORWARD
  • 慈善性法律援助
  • 管理层
    • Pricing & Alternative Fee Arrangements
    • AFA Models We Offer
    • Contingency Fees
    • AI + KM

James R. Barney

93% of IPR Claims Cancelled by PTAB in February Final Written Decisions

March 26, 2015

Managing Intellectual Property

Managing Intellectual Property sourced Finnegan’s AIA Blog for facts and data on Patent Trial and Appeal Board (PTAB) statistics in its article discussing canceled inter partes review (IPR) claims. According to the AIA Blog, in February, the PTAB canceled 93.2% of IPR claims that reached final written decision, which is far higher than the 70% average for all IPRs decided to date. That average does not include claims in which the board does not institute IPR, claims in challenged patents in which the parties to the IPR settled their dispute, and claims that have been canceled by a request for adverse judgment, a related reexamination, or a final court judgment. This high percentage could be an anomaly, or it may signify better odds by petitioners who go the distance.

Tags

Final Written Decision

Related Practices

专利局无效程序

PTAB无效程序:双方复审及授权后复审

Related News

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Commentary

New Appellate Opinion in Amazon Biometric Data Case May Signal ‘Narrowing’ Scope of BIPA Litigation, Experts Say

May 20, 2026

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Press Release

Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination

May 11, 2026

Commentary

ITC Bars Import of Innoscience Chips Made Before Redesign

May 8, 2026

Commentary

How Litigation Funding Disclosure Could Affect ITC Cases

May 7 , 2026

Award/Ranking

Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey

May 7, 2026

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Announcement

Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International

May 4, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 隐私
  • 免责申明
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP